Clinical Trial Update: Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating NY-ESO-1 TCR-engineered T cells with hematopoietic stem cells after melphalan conditioning in recurrent or refractory ovarian, fallop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Hematopoietic stem cells (hematopoietic stem cells)
• NY-ESO-1 TCR-engineered T cells (NY-ESO-1 TCR-engineered T cells)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Status: TERMINATED